MD611Z - Method for treatment of chronic atrophic gastritis - Google Patents
Method for treatment of chronic atrophic gastritis Download PDFInfo
- Publication number
- MD611Z MD611Z MDS20120036A MDS20120036A MD611Z MD 611 Z MD611 Z MD 611Z MD S20120036 A MDS20120036 A MD S20120036A MD S20120036 A MDS20120036 A MD S20120036A MD 611 Z MD611 Z MD 611Z
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- atrophic gastritis
- chronic atrophic
- silicon
- months
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 12
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 208000016644 chronic atrophic gastritis Diseases 0.000 title claims abstract description 8
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 9
- 239000010703 silicon Substances 0.000 claims abstract description 9
- 235000000008 Alchemilla vulgaris Nutrition 0.000 claims abstract description 7
- 241001408845 Alchemilla xanthochlora Species 0.000 claims abstract description 7
- 235000012054 meals Nutrition 0.000 claims abstract description 6
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 6
- 238000001802 infusion Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 abstract description 2
- 229940098465 tincture Drugs 0.000 abstract 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 7
- 208000006994 Precancerous Conditions Diseases 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229910003641 H2SiO3 Inorganic materials 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к медицине и может быть использовано для лечения хронического атрофического гастрита.Согласно изобретению метод лечения состоит в том, что вводят настойку Alchemilla vulgaris L.,содержащуюгидратированную коллоидную кремневую кислоту в количестве 0,12 г/100 мл, рассчитанную для кремния,по 200 мл, per os, 4 раза в день, за 20…30 мин до еды, в течение 4-х месяцев.The invention relates to medicine and can be used to treat chronic atrophic gastritis. According to the invention, the method of treatment consists in introducing tincture of Alchemilla vulgaris L. containing hydrated colloidal silicic acid in an amount of 0.12 g / 100 ml, calculated for silicon, 200 ml, per os, 4 times a day, 20 ... 30 minutes before meals, for 4 months.
Description
Invenţia se referă la medicină şi poate fi utilizată pentru tratamentul gastritei cronice atrofice. The invention relates to medicine and can be used for the treatment of chronic atrophic gastritis.
Se cunoaşte că depistarea şi tratamentul stărilor precanceroase ale stomacului reprezintă profilaxia secundară a cancerului gastric (Беспалов В. Г. Индивидуальная профилактика рака. Питер, 2001, с. 123-126). It is known that the detection and treatment of precancerous conditions of the stomach represents the secondary prophylaxis of gastric cancer (Беспалов V. G. Individual cancer prevention. Peter, 2001, pp. 123-126).
În prezent la principalele stări precanceroase ale stomacului se referă gastrita cronică atrofică şi infectarea cu Helicobacter pilori, iar la schimbările precanceroase principale se referă metaplazia intestinală şi displazia intestinală a epiteliului gastric (Аруин Л. И. Капуллер Л. Л. Исаков В. А. Морфологическая диагностика желудка и кишечника. Москва, Триада-Х, 1998, с. 269-300). Currently, the main precancerous conditions of the stomach include chronic atrophic gastritis and Helicobacter pylori infection, and the main precancerous changes include intestinal metaplasia and intestinal dysplasia of the gastric epithelium (Aruin L. I. Kapuller L. L. Isakov V. A. Morphological diagnosis of the stomach and intestines. Moscow, Triada-X, 1998, pp. 269-300).
Unul dintre factorii principali ai apariţiei cancerului gastric îl joacă compuşii ce conţin nitraţi şi amine în sucul gastric (Bartsch H., Frank N., Blocking the endogenous formation N-nitroso compounds and related carcenogens// In. Principles of Chemoprevention Ed. By. B. W. Stevart, D. Mc. Gregor, P. Kleihues - IARC Sci. Publ. Nr. 139, Lyon, France: International Agency for Research on Cancer, 1996, p. 189-201). One of the main factors in the occurrence of gastric cancer is played by compounds containing nitrates and amines in gastric juice (Bartsch H., Frank N., Blocking the endogenous formation N-nitroso compounds and related carcinogens// In. Principles of Chemoprevention Ed. By. B. W. Stevart, D. Mc. Gregor, P. Kleihues - IARC Sci. Publ. No. 139, Lyon, France: International Agency for Research on Cancer, 1996, p. 189-201).
Este cunoscută metoda de tratament al stărilor precanceroase gastrice, care constă în aceea că se administrează remediul KLAMIN (concentrat din Laminaria saccharina L. Lamour), care se obţine din fracţia lipidică a algelor brune de mare, câte 2 pastile de trei ori pe zi, cu 15…30 min înainte de masă, timp de 6 luni, cu repetarea curei de tratament peste 1…3 luni [1]. The method of treating gastric precancerous conditions is known, which consists in administering the remedy KLAMIN (concentrate from Laminaria saccharina L. Lamour), which is obtained from the lipid fraction of brown seaweed, 2 pills three times a day, 15…30 min before meals, for 6 months, with the treatment course repeated after 1…3 months [1].
Dezavantajul acestei metode constă în aceea că remediul KLAMIN conţine iod, din care cauză este contraindicat persoanelor care suferă de tireotoxicoză, insuficienţă renală şi hepatică cronică. The disadvantage of this method is that the KLAMIN remedy contains iodine, which is why it is contraindicated for people suffering from thyrotoxicosis, chronic renal and hepatic failure.
Se mai cunoaşte o metodă de tratament al stărilor precanceroase gastrice care constă în aceea că se administrează per os o compoziţie care conţine vitamina E şi β-caroten [2]. Another known method of treating gastric precancerous conditions consists in administering a composition containing vitamin E and β-carotene orally [2].
Dezavantajul acestei metode constă în aceea că compoziţia se administrează timp îndelungat, devenind posibilă cumularea vitaminei liposolubile în organism, ceea ce duce la manifestarea unui şir de efecte indezirabile. The disadvantage of this method is that the composition is administered for a long time, making it possible for the fat-soluble vitamin to accumulate in the body, which leads to the manifestation of a number of undesirable effects.
Problema pe care o rezolvă invenţia propusă constă în extinderea metodelor de profilaxie a stărilor precanceroase gastrice cu manifestarea unui efect mai superior şi mai stabil. The problem solved by the proposed invention consists in expanding the methods of prophylaxis of gastric precancerous conditions with the manifestation of a superior and more stable effect.
Conform invenţiei metoda de tratament constă în aceea că se administrează infuzie din Alchemilla vulgaris L., care conţine acid silicic coloidal hidratat în cantitate de 0,12 g/100 ml, calculat pentru siliciu, câte 200 ml, per os, de 4 ori pe zi, cu 20…30 min înainte de masă, timp de 4 luni. According to the invention, the treatment method consists in administering an infusion of Alchemilla vulgaris L., which contains hydrated colloidal silicic acid in an amount of 0.12 g/100 ml, calculated for silicon, 200 ml each, orally, 4 times a day, 20…30 min before meals, for 4 months.
Rezultatul invenţiei constă în extinderea metodelor de profilaxie a stărilor precanceroase gastrice care manifestă un efect sporit şi stabil. The result of the invention consists in expanding the methods of prophylaxis of gastric precancerous conditions which manifest an enhanced and stable effect.
Rezultatul se datorează combinării reuşite a ingredientelor atât cantitativ cât şi calitativ manifestând un sinergism, datorită cărui fapt componentele infuziei se potenţează eficace una pe alta. The result is due to the successful combination of ingredients both quantitatively and qualitatively, manifesting a synergism, due to which the components of the infusion effectively potentiate each other.
Pentru obţinerea infuziei din Alchemilla vulgaris L., ce conţine acid silicic coloidal în cantitate de 0,12 g/100ml, calculat pentru siliciu, destinată tratamentului gastritei cronice atrofice se pregăteşte materia primă din partea vegetală (partea aeriană) a Alchemilla vulgaris L., apoi materia primă se plasează într-un vas şi se toarnă apă la temperatura fierberii, apa şi materia vegetală se iau în raport de 10:1, după care în vas se adaugă siliciu în raport de 100:1, preventiv mărunţit până la fracţia de 0,01 mm. Infuzia se prelucrează într-un separator electromagnetic în scopul înlăturării impurităţilor metalice de pe suprafaţa siliciului mărunţit, obţinându-se infuzia din Alchemilla vulgaris L., ce conţine acid silicic coloidal în cantitate de 0,12 g/100 ml calculat pentru siliciu, gata de utilizare în tratamentul gastritei cronice atrofice. Infuzia obţinută se administrează per os, cu 20…30 min înainte de masă, de 4 ori pe zi, câte 200 ml, timp de 4 luni. To obtain the infusion of Alchemilla vulgaris L., containing colloidal silicic acid in an amount of 0.12 g/100 ml, calculated for silicon, intended for the treatment of chronic atrophic gastritis, the raw material is prepared from the plant part (aerial part) of Alchemilla vulgaris L., then the raw material is placed in a vessel and water is poured at boiling temperature, water and plant material are taken in a ratio of 10:1, after which silicon is added to the vessel in a ratio of 100:1, preventively crushed to a fraction of 0.01 mm. The infusion is processed in an electromagnetic separator in order to remove metallic impurities from the surface of the crushed silicon, obtaining the infusion of Alchemilla vulgaris L., containing colloidal silicic acid in an amount of 0.12 g/100 ml calculated for silicon, ready for use in the treatment of chronic atrophic gastritis. The resulting infusion is administered orally, 20…30 minutes before meals, 4 times a day, 200 ml each, for 4 months.
Siliciul reacţionează cu apa la temperatura fierberii, având următoarea reacţie chimică analogă cu cea a carbonului: Silicon reacts with water at boiling temperature, having the following chemical reaction analogous to that of carbon:
Si +2H2O → H2SiO3·n H2O + 2H2, Si +2H2O → H2SiO3·n H2O + 2H2,
unde H2SiO3·n H2O este în formă coloidală. where H2SiO3·n H2O is in colloidal form.
Exemplu concret de realizare a invenţiei Concrete example of realization of the invention
Bolnava C., 45 ani, suferă de gastrită cronică atrofică. Acuze la eructaţie cu miros fetid, greutate în regiunea epigastrică, meteorism, dureri gastrice ce se intensifică după alimentaţie. FEGPS - mucoasa gastrică atrofică, pliurile mucoase sunt denivelate. Bolnava a primit tratament conform metodei revendicate, adică, zilnic, per os, s-a administrat infuzie din Alchemilla vulgaris L., care conţine acid silicic coloidal în cantitate de 0,12 g/100 ml calculat pentru siliciu, câte 200 ml, cu 20…30 min înainte de masă, de 4 ori pe zi, timp de 2 luni. După aceasta, la investigaţiile efectuate ulterior s-a stabilit dispariţia semnelor clinice şi ameliorarea stării pacientei. Bolnava nu a avut efecte adverse de la administrarea infuziei, a continuat cura de tratament încă 2 luni. Patient C., 45 years old, suffers from chronic atrophic gastritis. Complaints of fetid-smelling belching, heaviness in the epigastric region, flatulence, stomach pain that intensifies after eating. FEGPS - atrophic gastric mucosa, mucosal folds are uneven. The patient received treatment according to the claimed method, i.e., daily, per os, infusion of Alchemilla vulgaris L. was administered, which contains colloidal silicic acid in an amount of 0.12 g/100 ml calculated for silicon, 200 ml each, 20…30 min before meals, 4 times a day, for 2 months. After this, subsequent investigations established the disappearance of clinical signs and improvement of the patient's condition. The patient had no adverse effects from the administration of the infusion, the treatment course continued for another 2 months.
Prin această metodă au fost trataţi 38 de pacienţi. Tratamentul s-a soldat cu succes, efecte adverse nu s-au înregistrat. 38 patients were treated with this method. The treatment was successful, no adverse effects were recorded.
1. RU 2034560 C1 1995.05.10 1. RU 2034560 C1 1995.05.10
2. WO 9102535 A1 1991.03.07 2. WO 9102535 A1 1991.03.07
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20120036A MD611Z (en) | 2012-02-14 | 2012-02-14 | Method for treatment of chronic atrophic gastritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20120036A MD611Z (en) | 2012-02-14 | 2012-02-14 | Method for treatment of chronic atrophic gastritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD611Y MD611Y (en) | 2013-03-31 |
| MD611Z true MD611Z (en) | 2013-10-31 |
Family
ID=48045152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20120036A MD611Z (en) | 2012-02-14 | 2012-02-14 | Method for treatment of chronic atrophic gastritis |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD611Z (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD783Z (en) * | 2013-10-08 | 2015-01-31 | Адриан КИШКА | Method for treating chronic atrophic gastritis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002535A1 (en) * | 1989-08-11 | 1991-03-07 | Basil, Inc. | Cancer prevention composition and method |
| RU2034560C1 (en) * | 1993-05-18 | 1995-05-10 | Товарищество с ограниченной ответственностью "Фитолон" | Cancer prevention "clamin" remedy |
-
2012
- 2012-02-14 MD MDS20120036A patent/MD611Z/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002535A1 (en) * | 1989-08-11 | 1991-03-07 | Basil, Inc. | Cancer prevention composition and method |
| RU2034560C1 (en) * | 1993-05-18 | 1995-05-10 | Товарищество с ограниченной ответственностью "Фитолон" | Cancer prevention "clamin" remedy |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD783Z (en) * | 2013-10-08 | 2015-01-31 | Адриан КИШКА | Method for treating chronic atrophic gastritis |
Also Published As
| Publication number | Publication date |
|---|---|
| MD611Y (en) | 2013-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Panee | Potential medicinal application and toxicity evaluation of extracts from bamboo plants | |
| KR20100084812A (en) | Composition for promoting proliferation of hematopoietic stem cell containing inonotus obliquus extract, phellinus linteus extract and ganoderma lucidum extract | |
| CN104415290A (en) | Stagnation-removing decoction oral liquid and preparation method thereof | |
| MD611Z (en) | Method for treatment of chronic atrophic gastritis | |
| WO2024001141A1 (en) | Use of herba agastachis stomach-calming prescription in preparation of drug for resisting helicobacter pylori | |
| WO2016085068A1 (en) | Composition for increasing exercise performance ability and enhancing physical strength, containing composite extract | |
| CN104068404A (en) | Health product with function of chloasma removal | |
| WO2011016652A2 (en) | Composition for controlling anal fistulae and method for preparing same | |
| CN101890062A (en) | Application of nard pine and its extract in the preparation of medicine for treating gastric ulcer | |
| CN106266023B (en) | Medicine for treating gastric ulcer and preparation method thereof | |
| CN100556402C (en) | Capsules for treating stomach problems | |
| CA2935895A1 (en) | Fractions of extracts of helichrysum having mucoadhesive properties | |
| KR102223638B1 (en) | PSA stabilizer in blood comprising antimicrobial composition containing silver compound and complexing agent and Panax notoginseng extract | |
| CN1306837A (en) | Application of Radix Polygoni Multiflori and its extract in preventing and treating osteoporosis | |
| CN102048824A (en) | Traditional Chinese medicine composition for treating cerebrovascular disease and application thereof | |
| CN110536690A (en) | Pharmaceutical composition for preventing or treating hepatitis C virus infection | |
| KR20040036092A (en) | Anticarcinogenic constituents of ginsenoside Rh2 and Rg3 | |
| MD783Z (en) | Method for treating chronic atrophic gastritis | |
| KR100558930B1 (en) | Purified extracts obtained from Harpagopitum procumbens and / or Harpagopitum J. heidens, preparation methods thereof and uses thereof | |
| CN105381125B (en) | Traditional Chinese medicine composition for preventing and treating influenza as well as preparation method and application thereof | |
| CN104491196A (en) | Traditional Chinese medicine preparation for treating gastrorrhagia | |
| HK40116366A (en) | Application of traditional chinese medicine compositions in the preparation of pharmaceuticals for preventing and treating viral infectious diarrhea | |
| CN106138259A (en) | A kind of Chinese medicine composition treating anemopyretic cold and preparation method thereof | |
| WO2021152555A1 (en) | Novel immunotherapy for tumours and cancers, and associated inflammation | |
| CN103239593B (en) | Chinese medicine effective part composition for treating chronic prostatitis and preparation method of Chinese medicine effective part composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |